Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.
Lilly to Invest $364 Million in UK Biotech, Obesity Research
Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...
Daily Reporter1h
Why Lilly is pouring billions into LEAP
Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...
Amgen downgraded at Truist on MariTide prospects for obesity
Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...
University of Manchester1h
New study to deepen understanding of a weight loss medication
Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...
Thousands of people with life-threatening obesity denied access to weight-loss jab Wegovy
Doctors have said access to the drug is a "postcode lottery" as Sky News analysis reveals just 800 people have been ...
Armed robbery in Revesby1h
Research to Unveil Insights on Weight Loss Medication
Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...
Tory leadership hopeful Robert Jenrick urges overweight Brits to copy him and use Ozempic to shed the pounds if their doctor recommends the drug
The former immigration minister, who lost four stone in 12 months, said the drug had aided him at the start of his bid to ...
One MILLION overweight Brits will be paying for fat jabs like Ozempic by this time next year
Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...
thedailyupside15h
Weight-Loss Drugs Might Not Tank Medicare After All
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...